and chronic respiratory failure. The prevalence of these abnormalities among patients completing anti-TB treatment is alarmingly high. In fact, some studies have suggested greater morbidity from the sequelae rather than from the disease itself. It is important to be aware of the full spectrum of these disorders to facilitate early diagnosis and management. 
A B S T R A C T Tuberculosis (TB) is among the top infectious causes of morbidity and mortality worldwide
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